Senti Biosciences Holdings, Inc. (SNTI)

Senti Biosciences is a biotech company working on a very specific problem: how to give immune cells the ability to hunt and kill cancer cells while leaving the patient’s own healthy cells alone. The company is clinical-stage, meaning it has moved its lead candidate into human testing but has not yet brought any therapy to market or generated significant revenue.

What the company does, in plain terms

Cancer is a disease where the body’s own cells mutate and multiply out of control. The immune system normally catches and kills these rogue cells, but sometimes the cancer cells find ways to hide or disable the immune response. Senti’s approach is to take immune cells called natural killer cells — which the body naturally uses to detect and kill abnormal cells — remove them from a patient, train them with extra genes to spot cancer specifically, and put them back into the bloodstream.

The extra genes Senti adds are called a CAR, which stands for chimeric antigen receptor. This receptor acts like a targeting system. It tells the natural killer cell to find and kill cells that carry a specific marker — in the case of Senti’s lead therapy, a marker found on leukaemia cells. The cells then return to the body and hunt for their target.

This is similar to an earlier approach called CAR-T therapy, which uses a different immune cell (a T cell). CAR-T has worked in some blood cancers but has significant downsides. The cells can be toxic to the patient, causing dangerous inflammatory reactions. T cells require expensive manufacturing for each patient. And they sometimes go rogue, multiplying out of control.

Senti’s idea is that natural killer cells behave differently. They are more controllable. They can be made from “off-the-shelf” donor cells rather than taken from each patient, which is cheaper and faster. And the company has added extra genes — what it calls gene circuits — that work like safety brakes, allowing doctors to control whether the cells activate or quiet down.

The company’s lead program

Senti’s most advanced program is SENTI-202, which targets a type of blood cancer called acute myeloid leukaemia, or AML. AML is a serious disease: patients’ bone marrows fill with immature cancer cells, crowding out normal blood production. Outcomes are poor, especially for older patients or those whose leukaemia has returned after initial treatment.

In early trial results released by the company, SENTI-202 showed meaningful activity. In patients with heavily treated, relapsed or refractory AML (meaning the disease had already resisted other therapies), about half responded to the treatment, and about 40 percent went into complete or near-complete remission. Those remission rates are encouraging for such a sick population. The drug regulators at the FDA gave the program a special “Regenerative Medicine Advanced Therapy” designation, which accelerates the review timeline and signals that regulators view the approach as potentially valuable.

Senti has also disclosed other programs in earlier development stages targeting other cancers and potentially other cell types.

The company’s money situation

As of the end of 2025, Senti reported 16 million dollars in cash on the balance sheet. That is the company’s runway — the amount it can burn before it must raise more capital. The company is burning cash steadily, with quarterly net losses in the range of 14 to 15 million dollars. At that burn rate, the company has roughly one year of operations before it needs another capital raise.

This is typical for a clinical-stage biotech. The company is not making money. It is spending money to fund the trials that will determine whether its therapies work. If the trials go well, the company attracts new investors. If they go poorly, the company runs out of money and may fail.

The company’s investors are betting that the SENTI-202 trial results are strong enough to convince new investors to fund the next phase of testing, and ultimately strong enough to support a regulatory approval and commercialization. The time between now and that outcome is likely years, not months.

The competitive landscape

Senti is not alone in pursuing natural killer cell therapies. Several other biotech companies and major pharmaceutical firms are pursuing similar approaches. CAR-T therapy, despite its downsides, has paved the way by proving that this genre of therapy can work in principle. The commercial opportunity is large — if any CAR-NK approach works well and wins approval, the addressable market includes every patient with AML, and potentially many more cancer types.

The risks are equally substantial. The mechanism might not work as hoped. The natural killer cells might not persist long enough in the body to be therapeutically useful. They might trigger unexpected toxicities. The manufacturing might prove more complex than current approaches. Another company’s approach might be simpler or more effective, reaching the market first and dominating the space.

The upside and downside

For investors, Senti represents a speculative bet on a new therapeutic approach at an early enough stage that success is far from certain. But if the therapy works, the market for a new treatment for AML — and potentially other cancers — is enormous. Cell therapies that work typically command premium prices, and patients with few alternatives will often accept significant side effects.

The company’s main near-term milestone is advancing SENTI-202 through its ongoing trials and demonstrating durable remissions and acceptable safety. If that happens, the company will likely attract major pharmaceutical partners or acquirers. If the data disappoints, the company will need to pivot, outlicense its technology to others, or wind down.

For anyone tracking the company, watching clinical trial results and announcements about partnerships or funding is the most relevant signal. The company’s cash burn rate and runway are equally important. Companies run out of money, and a strong trial result means nothing if the company cannot fund the next phase of development.